| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/13/2006 | US20060078595 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| 04/13/2006 | US20060078582 Use of compositions for treating rosacea |
| 04/13/2006 | US20060078554 Virus-like particle of an RNA bacteriophage carrier attached to an angiotensin peptide through a nonpeptide bond to form an ordered and repetitive angiotensin peptide-carrier conjugate; treating/preventing hypertension, stroke, infarction, congestive heart failure, kidney failure and retinal hemorrhage |
| 04/13/2006 | US20060078547 Lactobacillus salivarius strain, AH102, AH103, AH105, AH109 or AH110 or mutants or variants are useful in the prophylaxis and/or treatment undesirable gastrointestinal inflammatory activity, such as inflammatory bowel disease or irritable bowel syndrome |
| 04/13/2006 | US20060078545 Neural progenitor cell populations |
| 04/13/2006 | US20060078543 Neural progenitor cells derived from embryonic stem cells |
| 04/13/2006 | US20060078496 Method of drug delivery to interstitial regions of the myocardium |
| 04/13/2006 | CA2583326A1 Receptor function regulating agent |
| 04/13/2006 | CA2582752A1 Fluorophosphonocinnamic compounds, synthesis and uses for treating disorders caused by oxidative stress |
| 04/13/2006 | CA2582327A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | CA2581051A1 Pulmonary administration of an antithrombotic compound |
| 04/12/2006 | EP1645634A2 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/12/2006 | EP1645624A1 Nerve cells obtained by electrical pulse treatment es cell |
| 04/12/2006 | EP1645288A1 New nuclear transcription factors regulators |
| 04/12/2006 | EP1645282A1 Use of fibrinolytic metalloproteinases for treating blood clots |
| 04/12/2006 | EP1644742A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 04/12/2006 | EP1644509A1 Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis |
| 04/12/2006 | EP1644490A2 Transgenic cells |
| 04/12/2006 | EP1644385A1 Silicon compounds and their use |
| 04/12/2006 | EP1644360A1 3-substituted indoles and derivatives thereof as therapeutic agents |
| 04/12/2006 | EP1644345A1 Urea derivatives of piperazines and piperidines as fatty acid oxidation inhibitors |
| 04/12/2006 | EP1644086A1 Use of whey permeate for the treatment of metabolic syndrome |
| 04/12/2006 | EP1644026A2 Sigma ligands for neuronal regeneration and functional recovery |
| 04/12/2006 | EP1644009A2 Compositions and methods for increasing telomerase activity |
| 04/12/2006 | EP1644006A1 Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin |
| 04/12/2006 | EP1643988A1 Substituted pyrrole derivatives as hmg-coa reductase inhibitors |
| 04/12/2006 | EP1643983A2 Methods of inhibiting vascular permeability and apoptosis |
| 04/12/2006 | EP1560826B1 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same |
| 04/12/2006 | EP1423436B1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids |
| 04/12/2006 | EP1389213B1 3,7-diazabicyclo 3.3.1| formulations as antiarhythmic compounds |
| 04/12/2006 | EP1385858B1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof |
| 04/12/2006 | EP1345920B1 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/12/2006 | EP1336605B1 Substituted phenol derivatives or salts thereof as inhibitors of coagulation factor x |
| 04/12/2006 | EP1334174B1 Paramyxovirus vector for gene transfer to the cardiovascular system |
| 04/12/2006 | EP1331940B1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 04/12/2006 | EP1317272B1 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant |
| 04/12/2006 | EP1311499B1 Bicyclic compounds as h3 receptor ligands |
| 04/12/2006 | EP1311471B1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines |
| 04/12/2006 | EP1299089B1 Drug delivery system for poorly water soluble drugs |
| 04/12/2006 | EP1233767B1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 04/12/2006 | EP1192247B1 Sphingosine kinase enzyme |
| 04/12/2006 | EP1144435B1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 04/12/2006 | EP1140175B1 Antibodies to truncated vegf-d and uses thereof |
| 04/12/2006 | EP1087981B1 Prenyl transferase inhibitors |
| 04/12/2006 | EP1054887B1 Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists |
| 04/12/2006 | EP0938328B1 Method of inhibiting fibrosis with a somatostatin agonist |
| 04/12/2006 | CN1759103A Water-soluble phenylpyridazine derivative and medicine containing the same |
| 04/12/2006 | CN1758913A Use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species |
| 04/12/2006 | CN1757409A Recipe of Wanshou capsule, and health-care function |
| 04/12/2006 | CN1757403A Health-care medicated wine for treating hypertension disease |
| 04/12/2006 | CN1757400A Traditional Chinese medicine granule, and its prepn. method |
| 04/12/2006 | CN1250717C Human Enzymes of metalloprotease family |
| 04/12/2006 | CN1250706C Bottled glossy ganoderma, and production method and use thereof |
| 04/12/2006 | CN1250570C Binding molecules derived from immunolobulins which do not trigger complement mediated lysis |
| 04/12/2006 | CN1250551C Spirocyclic-6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines |
| 04/12/2006 | CN1250549C Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| 04/12/2006 | CN1250536C 4-aminobenzopyran derivatives |
| 04/12/2006 | CN1250526C Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 04/12/2006 | CN1250521C Acetyl l-carnitine salt and process for preparing same |
| 04/12/2006 | CN1250286C Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 04/12/2006 | CN1250281C Method for treating endothelium wound |
| 04/12/2006 | CN1250280C Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
| 04/12/2006 | CN1250256C Products as food or medicine against thrombus and cardiac and encephalic blood vessel diseases and reducing fat and their productions |
| 04/12/2006 | CN1250253C Preparation method of Chinese medicine capsule for treating ischemic cerebral apoplexy |
| 04/12/2006 | CN1250250C Ischemic cerebral vascular disease treating medicine |
| 04/12/2006 | CN1250243C Compound Chinese medical preparation for curing cardiovascular, cerebrovascular diseases and its preparing method |
| 04/12/2006 | CN1250242C Kudzu vine flavone capsule and its prepn. method |
| 04/12/2006 | CN1250228C Orally disintegrating tablet of pseuto-ginseng total saponins and its preparation |
| 04/12/2006 | CN1250223C Pyrrolo-triazine and pyrimidine compounds |
| 04/12/2006 | CN1250218C Use of angiotensin II antagonists |
| 04/12/2006 | CN1250209C Inhibitor for 20-hydroxy-eicosatetraenoic acid enzyme |
| 04/12/2006 | CN1250114C Health foods containing natto kinase and fermented milk products |
| 04/11/2006 | US7026516 Compounds with high monoamine transporter affinity |
| 04/11/2006 | US7026510 Inhibitors of the chemotactic activation induced by the fraction C5a of complement and from other chemotactic proteins (chemokines) that y activate a 7-transmembrane-domain receptor; psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, fibrosis; antiischemic agents |
| 04/11/2006 | US7026491 E.g., dimethylcarbamic acid, 2-oxo-3-benzyl-4-methyl-2H-1-benzopyran; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 04/11/2006 | US7026487 Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, a pyridyl group and an alkyl group, having retinoid-like biological activity |
| 04/11/2006 | US7026476 Intermediate arylamine compounds |
| 04/11/2006 | US7026469 Compositions and methods of double-targeting virus infections and cancer cells |
| 04/11/2006 | US7026462 Regulation of angiogenesis with zinc finger proteins |
| 04/11/2006 | US7026361 Dispersion stability; forming protective colloid; bioavailability; hypotensive agents, oral diseases |
| 04/11/2006 | US7026356 Fatty acid analogues for the treatment of diseases caused by the pathological proliferation of smooth muscle cells |
| 04/11/2006 | US7026355 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases |
| 04/11/2006 | US7026349 Sulfonamides |
| 04/11/2006 | US7026348 Antiinflammatory agents; sepsis shock; rheumatic diseases |
| 04/11/2006 | US7026336 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases |
| 04/11/2006 | US7026335 Melanocortin receptor ligands |
| 04/11/2006 | US7026331 Inhibitors of IkB kinase (I Kappa B Kinase); treating various diseases including asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cancer, infections, and cardiac infarct |
| 04/11/2006 | US7026326 Substituted heterocyclic compounds and methods of use |
| 04/11/2006 | US7026324 Amide containing a pyridinone or pyrazinone compound as serine protease enzyme inhibitors |
| 04/11/2006 | US7026321 piperazine derivatives, e.g., (2R)-1-(2-methylbenzothiazol-5-yloxy)-3-[4-({5-[4-(trifluoromethyl)phenyl](4,5-dihydroisoxazol-3-yl)}methyl)piperazinyl]propan-2-ol; treating diabetes, arrhythmia, intermittent claudication, angina, congestive heart disease, and myocardial infarction |
| 04/11/2006 | US7026320 Serotonergic agents |
| 04/11/2006 | US7026318 Compounds exhibiting X-type sPLA2 inhibiting effect |
| 04/11/2006 | US7026317 bind to corticotropin releasing factor (CRF) receptors; psychological disorders; anxiety-related disorders; central nervous system disorders |
| 04/11/2006 | US7026316 (optionally aza)cycloalkyl-N,N-optionally thia-, oxothia- or dioxothia-)alkyleneglycine derivatives, e.g., N-{4-[(1S)-1-amino-2-oxo-2-(1,3-thiazolidin-3-yl)ethyl]cyclohexyl}-N'-hexylureA; especially treating type 2 diabetes |
| 04/11/2006 | US7026314 Psychological disorders, antidepressants, anxiolytic agents, eating disorders; serotonin receptors antagonist |
| 04/11/2006 | US7026311 Dibenzodiazepine derivatives, their preparation and use |
| 04/11/2006 | US7026297 Neuroprotective agents |
| 04/11/2006 | US7026293 Comprising active ingredient such as atrial natriuretic peptide which can increase cGMP production by acting on natriuretic peptide receptor, and which reduces an infarct region |
| 04/11/2006 | US7026284 Formative agent of protein complex |
| 04/11/2006 | US7025987 Delivery system for nucleic acids |